Bioactivity | Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages[1][2][3]. |
Invitro | Resiquimod (GMP) (3 µg/mL,5 天) 诱导人 mMDSC 成熟为炎性巨噬细胞 (MACinflam)[1]。Resiquimod (GMP) (3 µg/mL,3 天) 在人 mMDSC 中产生 IL-6 和 IL-12[1]。Resiquimod (GMP) (2.5 µg/mL,7 天) 将记忆 B 细胞转分化为产生 IgG 的浆细胞[2]。Resiquimod (GMP) (5 µg/mL,5 天) 诱导 MDSCs 分化为成熟的骨髓细胞[3]。 |
Name | Resiquimod (GMP) |
CAS | 144875-48-9 |
Formula | C17H22N4O2 |
Molar Mass | 314.38 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Bayik D, et al. Factors Influencing the Differentiation of Human Monocytic Myeloid-Derived Suppressor Cells Into Inflammatory Macrophages. Front Immunol. 2018 Mar 26;9:608. [2]. Preisendörfer S, et al. FK506-Binding Protein 11 Is a Novel Plasma Cell-Specific Antibody Folding Catalyst with Increased Expression in Idiopathic Pulmonary Fibrosis. Cells. 2022 Apr 14;11(8):1341. [3]. Lee M, et al. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch Pharm Res. 2014;37(9):1234-40. |